Article Text

Download PDFPDF

5PSQ-024 Effectiveness and safety of durvalumab in the treatment of unresectable locally advanced non-small-cell lung cancer (LA-NSCLC)
  1. Z Rodríguez Fernández1,
  2. B Távara Silva2,
  3. B Matilla Fernández1,
  4. X Casás Fernández1,
  5. A Vélez Blanco1,
  6. JC Sáez Hortelano1,
  7. C De Castro Avedillo1,
  8. R Varela Fernández1,
  9. A Martín Sanz1,
  10. C Guindel Jiménez1,
  11. C Arenós Monzó1
  1. 1León University Hospital, Hospital Pharmacy, León, Spain
  2. 2León University Hospital, Medical Oncology, León, Spain


Background and importance Unresectable locally advanced non-small cell lung cancer (LA-NSCLC) long-term survival is poor. Durvalumab is approved as consolidation treatment in unresectable LA-NSCLC, without progression after chemoradiotherapy including platinum, with PD-L1 ≥1%.

Aim and objectives To analyse the effectiveness and safety of durvalumab in the treatment of unresectable LA-NSCLC compared with the results of the pivotal study (PACIFIC). Secondary objective was influence of PD-L1 expression on effectiveness.

Material and methods Retrospective observational study of patients with unresectable LA-NSCLC treated with durvalumab in a tertiary hospital (August 2018–October 2021).

Variables studied (electronic medical history): sex, age, Eastern Cooperative Oncology Group (ECOG), smoking, PD-L1, histology, disease stage. Variable to evaluate effectiveness: progression-free survival (PFS) from the start of treatment. For safety: adverse events (AE) and toxicity grade according to the Common Terminology Criteria for Adverse Events v5.0. Statistical analysis performed with SPSS v.23 software.

Results Thirty-one patients were included, mean age 66.45 (±9.45) years, male (74.2%), smokers (64.5%), ex-smokers (35.5%), World Health Organization (WHO) performance status: ECOG 0 (74.2%), ECOG 1 (25.8%). Disease stage IIIA (25.8%), IIIB (48.4%), IIIC (25.8%), squamous histology (41.9%), adenocarcinoma (41.9%) and unspecified (16.1%).

41.9% received induction chemotherapy. Most common chemotherapy was cisplatin-vinorelbine (48.4%). Durvalumab was initiated a median of 55 (35–70) days after chemoradiotherapy. After initiating durvalumab, the median follow-up was 15 (5–22) months. Received a median of 13 (8–26) cycles. 35.5% (n=11) of patients completed 12 months of treatment, 29% (n=9) remain on treatment. Treatment discontinuation was 22.6% (n=7) due to disease progression and 12.9% (n = 4) due to severe toxicity. 51.6% (n = 16) presented toxicity associated with durvalumab: 68% (n=11) grade 1–2 toxicity. Main AEs: thyroid (19.32%) and cutaneous (22.54%) alterations.

Median PFS was 14 (95% CI 7.59 to 20.4) months, with a PFS rate at 12 months (PFS12m): 70.6%. PFS12m was: 25% in PD-L1 <1% (n=4); 50% in PD-L1 1%–49% (n=10) and 73.33% in PD-L1 ≥50% (n=15).

Conclusion and relevance Our results showed, compared with the PACIFIC study, a lower median PFS (14 vs 17 months) and a higher PFS12m (70.6% vs 55.7%), results that seem comparable. In terms of safety, the results are similar to those of the PACIFIC study, so there is a good safety profile in our patients. The data analysed showed a lower effectiveness in PD-L1 <1%. However, a larger sample and follow-up are required to obtain conclusive results.

Conflict of interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.